This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation

This study has been completed.
Information provided by (Responsible Party):
Yaling Han, Shenyang Northern Hospital Identifier:
First received: March 26, 2010
Last updated: June 13, 2012
Last verified: June 2012
Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests. This multicenter, randomized study is aimed to explore the efficacy and safety of intensive antiplatelet therapy (i.e. double clopidogrel maintenance dose and/or additional cilostazol)for patients with CR after coronary stenting.

Condition Intervention Phase
Acute Coronary Syndromes Percutaneous Coronary Intervention Clopidogrel Low Responsiveness Drug: aspirin, clopidogrel Drug: aspirin, clopidogrel, cilostazol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Yaling Han, Shenyang Northern Hospital:

Primary Outcome Measures:
  • Major ischemic cardiovascular events [ Time Frame: 1 year ]
    defined as a composite of cardiac death, myocardial infarction or stroke

Secondary Outcome Measures:
  • Stent thrombosis [ Time Frame: 1 year ]
    according to ARC definition

  • major adverse cardiac and cerebral events(MACCE) [ Time Frame: 1 year ]
    defined as a composite of cardiac death, myocardial infarction, target vessel revascularization or stroke

  • Hemorrhagic events [ Time Frame: within 1 year ]
    according to TIMI bleeding definition

  • reduction in ADP induced platelet aggregation [ Time Frame: 30 days ]
    assessed by LTA (Packs-4 Aggregometer, Helena labs, Beaumont, Texas)

Enrollment: 840
Study Start Date: March 2009
Study Completion Date: June 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: standard group
patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
Drug: aspirin, clopidogrel
patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
Experimental: intensive group
patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
Drug: aspirin, clopidogrel, cilostazol
Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.


Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criterial:

  • aged 35 to 75 years
  • acute coronary syndromes
  • underwent successful coronary stent implantation
  • informed consent

Exclusion Criteria:

  • contraindications to antiplatelet therapy
  • history of intracranial bleeding
  • known bleeding disorders
  • severe liver or kidney disease
  • pregnancy
  • left main coronary artery disease
  • planned non cardiac surgery within 1 year
  • end stage of other serious disease with life expectancy less than 1 year
  • heart failure with NYHA grade 3 to 4
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01094457

China, Liaoning
463 Hospital of PLA
Shenyang, Liaoning, China, 110000
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110016
Shenyang Northern Hospital
Shenyang, Liaoning, China, 110840
Sponsors and Collaborators
Shenyang Northern Hospital
Principal Investigator: Yaling Han, MD Shenyang Northern Hospital
  More Information

Responsible Party: Yaling Han, vice president, Shenyang Northern Hospital Identifier: NCT01094457     History of Changes
Other Study ID Numbers: 825004-5
Study First Received: March 26, 2010
Last Updated: June 13, 2012

Keywords provided by Yaling Han, Shenyang Northern Hospital:
antiplatelet therapy
clopidogrel low responsiveness
acute coronary syndromes
percutaneous coronary intervention

Additional relevant MeSH terms:
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Cytochrome P-450 CYP2C19 Inhibitors processed this record on September 19, 2017